Allogene Therapeutics, Inc. ALLO
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2018 · data as of November 13, 2026
Allogene Therapeutics, Inc. (ALLO) is a healthcare company listed in the US with a market value of about $291M. In the twelve months to September 30, 2026 it had revenue of $5M and net income of -$174M, a net margin of -3760.0%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -41%.
About Allogene Therapeutics
Allogene Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2018. Revenue went from $114M in 2021 to $3M in 2025, a decline of about 61.1% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 54% over three years (dilution for shareholders). It spends 5775% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $5M | $3M | $100000 | $95000 | $156000 | $114M | $0 |
| Net income | -$174M | -$191M | -$258M | -$327M | -$340M | -$182M | -$316M |
| Free cash flow | -$109M | -$150M | -$201M | -$239M | -$226M | -$206M | -$181M |
| EPS (diluted) | $-0.61 | $-0.87 | $-1.32 | $-2.09 | $-2.38 | $-1.34 | $-2.63 |
| Net margin | -3760.0% | -7341.8% | -257600.0% | -344500.0% | -218200.0% | -159.6% | — |
| ROIC | — | -55.7% | -42.1% | -54.0% | -34.5% | -18.1% | -24.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $9.00, 973% above the current price; targets range from $4.00 to $14.00; the consensus rating is “Strong buy”; expected EPS is $-0.58 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Allogene Therapeutics pay a dividend?
Not currently.
Is Allogene Therapeutics a good stock to buy?
We do not give buy or sell advice. Allogene Therapeutics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.